ABSTRACT Introduction: The clinical manifestations of cutaneous adverse drug reactions are variable with different severity. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs)… Click to show full abstract
ABSTRACT Introduction: The clinical manifestations of cutaneous adverse drug reactions are variable with different severity. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions (SCARs) majorly caused by drugs and mediated by cytotoxic T cells. Areas covered: In this review, we focus on risk factors that contribute to the development of SJS/TEN and review the updated immune mechanism, preventive strategies as well as current therapeutic approaches for SJS/TEN. Expert opinion: The progress of SJS/TEN researches reveals that cytotoxic T cells majorly activated by drug interacted with the human leukocyte antigen (HLA) and T cell receptors play an important role for the immune mechanism of SJS/TEN. Several clinical assessment tools and in vitro drug-T cells activation tests have been developed to identify the causality of SJS/TEN. New therapeutic approaches and biologics such as TNF-alpha antagonist have been conducted to improve the prognosis of SJS/TEN.
               
Click one of the above tabs to view related content.